Evidence map›Paper›PMID 37426148›Full record

ArticleJournal of thoracic disease2023

Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities.

Harpreet Singh, Lipisha Agarwal, Chinmay Jani, Padmanabh Bhatt, Adam Hartley, Joseph Shalhoub, Jonathan S Kurman, Omar Al Omari, Alaaeldin Ahmed, Dominic C Marshall and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Short-term outcomes of acute heart failure hospitalizations in Ethiopia: A multicenter prospective study.American heart journal plus : cardiology research and practice · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Harpreet SinghDivision of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Lipisha AgarwalMedical Data Research Collaborative, London, UK.
Chinmay JaniMedical Data Research Collaborative, London, UK.
Padmanabh BhattMedical Data Research Collaborative, London, UK.
Adam HartleyMedical Data Research Collaborative, London, UK.
Joseph ShalhoubMedical Data Research Collaborative, London, UK.
Jonathan S KurmanDivision of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Omar Al OmariMedical Data Research Collaborative, London, UK.
Alaaeldin AhmedDepartment of Medicine, Mount Auburn Hospital/Beth Israel Lahey Health, Cambridge, MA, USA.
Dominic C Marshall *Medical Data Research Collaborative, London, UK.
Justin D Salciccioli *Medical Data Research Collaborative, London, UK.
Health Data Research UK · GBMedical College of Wisconsin · USBrigham and Women's Hospital · USHarvard University · USImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary hypertension (PH) is an independent risk factor for morbidity and mortality. In the last two decades, significant advances have been made in management of World Health Organization (WHO) group 1 PH. However, there are no approved targeted pharmacotherapies for PH secondary to left-sided heart diseases or chronic hypoxic lung diseases which are thought to account for more than 70-80% of the disease burden. No recent investigation has analyzed and compared the mortality burden related to WHO group 1 PH with the mortality burden with WHO groups 2-5 PH at the national level in the United States (US). We hypothesize that WHO group 1 PH-related mortality has improved over the last two decades in comparison to WHO groups 2-5 PH. Methods: In this study, we used data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) the underlying cause of death database to study age-standardized mortality rates related to PH in the US from 2003 to 2020. Results: A total of 126,526 deaths were recorded from PH in the US between 2003 and 2020. Across the study period, PH-related ASMR increased from 17.81 per million population in 2003 to 23.89 in 2020 with a percentage change (PC) of +34%. However, there are contrasting mortality trends in WHO group 1 PH when compared to WHO groups 2-5 PH. Data demonstrated a decline in mortality from group 1 PH regardless of gender. In contrast, an increase in mortality from WHO groups 2-5 PH was observed, accounting for the major proportion of the overall PH mortality burden in recent years. Conclusions: PH-related mortality continues to an increase primarily due to increase in mortality attributed to WHO groups 2-5 PH. These findings have notable public health implications. Screening and risk assessment tools for secondary PH, risk factor modification, and novel management strategies are vital to improve outcomes.

Indexed as

mortalityPulmonary hypertension (PH)United States (US)

Identifiers

PMID37426148
PMCPMC10323561
OpenAlexW4382727230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.